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hepatitis as defined by spontaneous PSE (8). Thus this 
study agrees in large measure with this conclusion, 
extending the benefit to nonencephalopathic patients 
with severe hepatic decompensation. However, a 
number of questions remain. What is the mode of 
therapeutic action of steroid therapy? Is prednisolone, 
the initial hepatic metabolite of prednisone, more 
effective? Interestingly, this drug at this dose and for 
this period of time exactly reproduces the first positive 
trial 20 years ago! The North Carolina group produced 
two positive trials with the randomization of only 37 and 
14 patients respectively. What irony! What is the optimal 
dose regime for this therapy? Finally, having salvaged 
the patients from early death, should one then introduce 
long-term therapy with agents such as propylthiouracil 
(9) or colchicine (10) to prevent a death later? That is, 
should the patient be enrolled in a therapeutic program 
rather than be allowed to die from the same cause 
sometime in the future? 
The answer to these and other questions will have to 
await further careful studies. In the meantime, we 
appear to have made significant progress in the acute 
treatment of severe alcoholic hepatitis. 
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STATISTICS AND CLINICAL TRIALS: THE CASE OF 
PREDNISOLONE IN ALCOHOLIC HEPATITIS 
The paper by b o n d  et al. is the latest in a series of 
studies that address the effect of prednisolone or similar 
compounds on survival in patients with acute alcoholic 
hepatitis. All are well designed and carefully controlled. 
This paper is no exception. The recommendations made 
on the basis of all these publications, however, are 
inconsistent. Why, in such a deceptively simple disease? 
First, an element of unpredictability is seen in patients 
with alcoholic liver disease. It has been known for some 
time that treatment with steroids lowers life expectancy 
in patients with alcoholic cirrhosis (11, yet there is a 
rationale to evaluate their use in patients with alcoholic 
hepatitis even though many patients’ studies have both 
cirrhosis and alcoholic hepatitis. Which lesion is dom- 
inant? Secondly, the patient sample evaluated may be 
heterogeneous. Patients could gain entry to this study 
by exceeding a value of 32 of Maddrey’s discriminant 
function (D.F.), (2), having encephalopathy or both. 
Given that the D.F. is composed of only two elements 
(the serum bilirubin concentration and prothrombin 
time) and assuming that no patient with a prothrombin 
ratio greater than 1.5 will have a biopsy, it can be 
calculated that patients who meet the entry criteria will 
fall within a range of minimum serum bilirubin concen- 
tration of 4.9 mg/dl and a prothrombin time of about 18 
sec, or a normal prothrombin time and a bilirubin 
concentration of at least 32 mg/dl. The fact that 15 of the 
patients meeting these criteria also had encephalopathy 
does not necessarily modify the homogeneity of this 
group. However, patients with less abnormal pro- 
thrombin times and bilirubin concentrations could 
qualify for entry primarily on the basis of encepha- 
lopathy, suggesting the possibility that the study popu- 
lation was indeed heterogeneous. In this instance the 
impact of this reservation is small because it accounts for 
only four patients. A third and serious problem illus- 
trated by this article is the requirement that placebo and 
treatment groups be truly similar. Ramond et al. have 
been singularly unfortunate because, despite their 
painstaking efforts to randomize at the time treatment 
started, the prednisolone group was much less ill than 
the control group, thus favoring a treatment effect. 
True, no “statistically significant” differences were 
found, but this may not be the issue. The objective is not 
to prove “non-difference” but reasonable similarity. 
Both groups of patients started off with similar D.F.s, 
and the D.F. increased during the waiting period. In the 
prednisolone group this increase was significant 
(p < 0.05); in the placebo group this was much more 
striking (p -= 0.025). Hence, at randomization the dif- 
ferences between groups could be calculated to have a p 
value of about 0.1, indicating a substantial probability 
that the two groups were indeed different. Doubts about 
the similarity of the two groups are increased when the 
creatinine values were examined. Expressed as mul- 
tiples of upper limit of normal at randomization, the 
prednisolone group had a value of 0.79 f 0.1 mg/dl, and 
the placebo group had a value of 0.98 ? 0.11 mg/dl. This 
suggests that almost one half of the placebo-treated 
patients had an abnormal serum creatinine value at 
randomization, compared with substantially fewer in 
the controls. 
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Clinicians have been trained to use statistics to 
identify differences and to reject apparent differences 
that may have occurred by chance. The objective of 
studies such as that by Ramond et al. is not to prove that 
the groups of patients are different at randomization but 
that they are similar. Similarity and therefore compa- 
rability are not necessarily the same as statistical 
nondifference. However, although it is reasonable to 
insist that differences at randomization should not favor 
the treatment effect, it is obviously unreasonable to 
insist that the groups should be similar to the point of 
near identify (i.e., a p value approaching 1). This issue 
may need to be addressed in a different context. 
It has been suggested that steroids should be withheld 
in the management of patients with alcoholic hepatitis 
“even in desperation” (3). Ramond et al. have made 
another dent in that recommendation even if it is not as 
deep as initial inspection of the data suggests. However, 
they have served us well by raising another question that 
interaction with our statistical colleagues may be able to 
address. 
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Editor’s note: The earlier version of the next review 
appeared in the May issue (HEPATOLOGY 1992; 15:973- 
974). The updated version is published below. The editor 
regrets the error. 
HEPATITIS A-NEW INFORMATION ON AN 
OLD VTRUS 
Rosenblum LS, Villarino ME, Nainan OV, Melish ME, 
Hadler SC, Pinsky PP, Jarvis WR, et al. Hepatitis A 
outbreak in a neonatal intensive care unit: risk factors 
for transmission and evidence of prolonged viral ex- 
cretion among preterm infants. J Infect Dis 1991;164: 
476-482. 
ABSTRACT 
An outbreak of hepatitis A virus (HAW infection in a 
neonatal intensive care unit (NICU) provided the 
opportunity to examine the duration of HAV excretion 
in infants and the mechanisms by which HAV epi- 
demics are propagated in NICUs. The outbreak af- 
fected 13 NICU infants (20%), 22 NICU nurses (24%), 8 
other staff caring for NICU infants, and 4 household 
contacts; 2 seropositive infants (primary -1 re- 
ceived blood transfueions from a donor with HAV 
infection. Risk factors for infection among nursea were 
care for a primary infant-case (relative risk IRRI, 3.21, 
drinking beverages in the unit (odds ratio [OR], m), 
and not wearing gloves when taping an intravenous 
line (OR., 13.7). Among infants, risk factors were care by 
a nurse who cared for a primary infant-caae during the 
same shift (RR, 6.1). Serial stool samples from infant- 
cases were tested for HAV antigen (HAV-Ag) by enzyme 
immunoassay and HAV RNA by nucleic acid amplifi- 
cation using the polymerase chain reaction. Infant- 
cases excreted HAV-Ag (n = 2) and HAV RNA (n = 3) 
4-5 months after they were identified as being infected. 
Breaks in infection control procedures and possibly 
prolonged HAV shedding in infants propagated the 
epidemic in a critical care setting. 
COMMENTS 
Hepatitis A virus (HAW has been a known important 
cause of viral hepatitis since the discovery of the viral 
antigen in feces in 1973 (1). Despite improvements in 
sanitation and the strict attention paid to infection 
control in most neonatal intensive care units (NICUs) 
several large outbreaks of HAV infection have occurred 
in these settings during the last decade (2-5). Although 
HAV infection is usually spread by way of a fecal-oral 
route, the index case in this report and others (3,4) was 
not an infected health care worker or parent but an 
infant who received a blood transfusion contaminated 
with HAV. Transmission of HAV by blood transfusion is 
uncommon, but donors in the prodromal phase of 
infection have been shown to transmit the virus by way 
of blood transfusion. HAV viremia is estimated to last at 
most 2 to 3 wk and occurs during the late incubation 
period of the virus. During this incubation period the 
donor’s AST and ALT are often normal, and thus 
contaminated blood is not identified by AST or ALT 
screening (5). As expected from previous studies, there 
was no evidence in this report for direct maternal-fetal 
transmission of HAV infection (6). 
Obviously, breaks occurred in infection control pro- 
cedures used in NICUs because 24% of the susceptible 
full-time nursing personnel, 16% of the respiratory 
technicians and 20% of the infants became infected 
before the identification of the epidemic. Furthermore, 
two household contacts of infected nurses and two 
family members of infected infants also had HAV 
infection develop. The novel and important findings in 
this study were that the authors were able to identify 
risk factors for the subsequent infection of health care 
personnel and infants. Not surprisingly, those nurses 
who cared for one of the two primary infant cases were 
3.2 times more likely to be infected than nurses who had 
not cared for these infants during the period of active 
infection. Other risk factors for HAV infection included 
working the night shift, those that facilitate contami- 
nation of the hands (not wearing gloves when taping 
intravenous lines or endotracheal tubes and having long 
